These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 23158694)

  • 41. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
    Huang MY; Armstrong AW
    Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased frequency of a unique spleen tyrosine kinase bright memory B cell population in systemic lupus erythematosus.
    Fleischer SJ; Giesecke C; Mei HE; Lipsky PE; Daridon C; Dörner T
    Arthritis Rheumatol; 2014 Dec; 66(12):3424-35. PubMed ID: 25156507
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases.
    Pamuk ON; Tsokos GC
    Arthritis Res Ther; 2010; 12(6):222. PubMed ID: 21211067
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Healing the Syk through kinase inhibitors.
    Rivera J; Colbert RA
    N Engl J Med; 2010 Sep; 363(14):1362-4. PubMed ID: 20879886
    [No Abstract]   [Full Text] [Related]  

  • 45. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
    Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Spleen tyrosine kinases: biology, therapeutic targets and drugs.
    Riccaboni M; Bianchi I; Petrillo P
    Drug Discov Today; 2010 Jul; 15(13-14):517-30. PubMed ID: 20553955
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Leptin and Neutrophil-Activating Peptide 2 Promote Mesenchymal Stem Cell Senescence Through Activation of the Phosphatidylinositol 3-Kinase/Akt Pathway in Patients With Systemic Lupus Erythematosus.
    Chen H; Shi B; Feng X; Kong W; Chen W; Geng L; Chen J; Liu R; Li X; Chen W; Gao X; Sun L
    Arthritis Rheumatol; 2015 Sep; 67(9):2383-93. PubMed ID: 25989537
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
    Otón T; Silva-Fernández L; Andreu JL
    N Engl J Med; 2011 Jan; 364(1):83; author reply 84. PubMed ID: 21208114
    [No Abstract]   [Full Text] [Related]  

  • 50. The Syk kinase as a therapeutic target in leukemia and lymphoma.
    Efremov DG; Laurenti L
    Expert Opin Investig Drugs; 2011 May; 20(5):623-36. PubMed ID: 21438742
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sesquiterpene dimmer (DSF-27) inhibits the release of neuroinflammatory mediators from microglia by targeting spleen tyrosine kinase (Syk) and Janus kinase 2 (Jak2): Two major non-receptor tyrosine signaling proteins involved in inflammatory events.
    Zeng KW; Wang S; Dong X; Jiang Y; Jin HW; Tu PF
    Toxicol Appl Pharmacol; 2014 Mar; 275(3):244-56. PubMed ID: 24486434
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Platelets and tyrosine kinase inhibitors: clinical features, mechanisms of action, and effects on physiology.
    Zheng TJ; Parra-Izquierdo I; Reitsma SE; Heinrich MC; Larson MK; Shatzel JJ; Aslan JE; McCarty OJT
    Am J Physiol Cell Physiol; 2022 Oct; 323(4):C1231-C1250. PubMed ID: 35938677
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting interferons and their pathways in systemic lupus erythematosus.
    Chasset F; Arnaud L
    Autoimmun Rev; 2018 Jan; 17(1):44-52. PubMed ID: 29108825
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Refractory alopecia in lupus treated with tofacitinib - a case-based review.
    Sarkar R; Mv P; Hinduja N; Sethy M; Kar H; Ahmed S
    Clin Rheumatol; 2023 Aug; 42(8):2237-2241. PubMed ID: 37188961
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus.
    Chyuan IT; Tzeng HT; Chen JY
    Cells; 2019 Aug; 8(9):. PubMed ID: 31450787
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
    Danilov AV
    Clin Ther; 2013 Sep; 35(9):1258-70. PubMed ID: 24054703
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
    Okamoto H; Kobayashi A
    N Engl J Med; 2011 Jan; 364(1):83-4; author reply 84. PubMed ID: 21208113
    [No Abstract]   [Full Text] [Related]  

  • 58. B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
    Hill RJ; Lou Y; Tan SL
    Int Rev Immunol; 2013 Aug; 32(4):377-96. PubMed ID: 23886341
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Syk inhibitors with high potency in presence of blood.
    Thoma G; Blanz J; Bühlmayer P; Drückes P; Kittelmann M; Smith AB; van Eis M; Vangrevelinghe E; Zerwes HG; Che JJ; He X; Jin Y; Lee CC; Michellys PY; Uno T; Liu H
    Bioorg Med Chem Lett; 2014 May; 24(10):2278-82. PubMed ID: 24726806
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting the B cell receptor pathway in chronic lymphocytic leukemia.
    Davids MS; Brown JR
    Leuk Lymphoma; 2012 Dec; 53(12):2362-70. PubMed ID: 22616724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.